Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alexion Secures Funding OK In England For GI Bleeding But Wants More

Company Is Seeking Coverage For Treatment Of Intracranial Hemorrhage

Executive Summary

Alexion is collecting more evidence to convince NICE that its anticoagulant reversal agent is also cost-effective for intracranial hemorrhage.

You may also be interested in...



AZ's Alexion Acquisition Looks Astute Bit Of Business

Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.

Portola Unruffled By NICE’s Rejection Of Ondexxya

Although the health technology assessment institute for England has provisionally recommended against the use of Europe’s first and only approved drug for reversing the effects of factor Xa anticoagulants, Portola believes it may now have the evidence needed to reverse this decision.

Cough Medicines Containing Pholcodine To Be Withdrawn In EU

The opioid, which has been used as a cough suppressant since the 1950s, should no longer be marketed, according to a safety review by the European Medicines Agency.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel